Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Shen, Min ^a   Zhang, Yaqin ^a   Saba, Nakhle ^b   Austin, Christopher P ^a   Wiestner, Adrian ^b   Auld, Douglas S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHLORAMBUCIL; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; TENIPOSIDE; VINBLASTINE;

ADULT; AGED; ARTICLE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG SCREENING; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE; MALE; QUANTITATIVE ANALYSIS; TOXICITY TESTING;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CASPASES; CELL SURVIVAL; CELLS, CULTURED; ENZYME ACTIVATION; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LUMINESCENT MEASUREMENTS; LYMPHOCYTES; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; SMALL MOLECULE LIBRARIES;

EID: 84884472431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075252     Document Type: Article

References (53)

1. Chiorazzi N, Rai KR, Ferrarini M, (2005) Chronic lymphocytic leukemia. N Engl J Med 352: 804-815. doi:10.1056/NEJMra041720. PubMed: 15728813.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456. doi:10.1182/blood-2007-06-093906. PubMed: 18216293.
3. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, et al. (2007) Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109: 4679-4685. doi:10.1182/blood-2005-12-051458. PubMed: 17299097.
4. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, et al. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112: 1923-1930. doi:10.1182/blood-2007-05-092882. PubMed: 18577710.
5. Gribben JG, O'Brien S, (2011) Update on therapy of chronic lymphocytic leukemia. J Clin Oncol 29: 544-550. doi:10.1200/JCO.2010.32.3865. PubMed: 21220603.
6. Sellner L, Dietrich S, Dreger P, Glimm H, Zenz T, (2012) Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia? Curr Hematol Malig Rep 7: 3-12. doi:10.1007/s11899-011-0110-1. PubMed: 22237849.
7. Tam CS, Keating MJ, (2010) Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol 7: 521-532. doi:10.1038/nrclinonc.2010.101. PubMed: 20603650.
8. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, et al. (1988) Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30: 457-459. PubMed: 2464793.
9. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, et al. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19-25. PubMed: 2473795.
10. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, et al. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101: 6-14. doi:10.1182/blood-2002-04-1258. PubMed: 12393429.
11. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, et al. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-3561. doi:10.1182/blood.V99.10.3554. PubMed: 11986207.
12. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, et al. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376: 1164-1174. doi:10.1016/S0140-6736(10)61381-5. PubMed: 20888994.
13. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, et al. (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112: 975-980. doi:10.1182/blood-2008-02-140582. PubMed: 18411418.
14. Blommel ML, Blommel AL, (2007) Pregabalin: An antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 64: 1475-1482. doi:10.2146/ajhp060371. PubMed: 17617497.
15. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, et al. (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35: 502-514. PubMed: 18278830.
16. Spaeth M, (2008) Is pregabalin a safe and effective treatment for patients with fibromyalgia? Nat Clin Pract Rheumatol 4: 514-515. doi:10.1038/ncpendmet0941. PubMed: 18762786.
17. Lacro RV, Dietz HC, Wruck LM, Bradley TJ, Colan SD, et al. (2007) Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. Am Heart J 154: 624-631. doi:10.1016/j.ahj.2007.06.024. PubMed: 17892982.
18. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, et al. (2010) Identification of a Primary Target of Thalidomide Teratogenicity. Science 12: 1345-1350.
19. Jacobson JM, (2000) Thalidomide: a remarkable comeback. Expert Opin Pharmacother 1: 849-863. doi:10.1517/14656566.1.4.849. PubMed: 11249521.
20. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, et al. (2011) The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Sci Transl Med 3: 80ps16. PubMed: 21525397.
21. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, et al. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951. doi:10.1182/blood-2002-10-3306. PubMed: 12595313.
22. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 103: 11473-11478. doi:10.1073/pnas.0604348103. PubMed: 16864780.
23. Fan F, Wood KV, (2007) Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 5: 127-136. doi:10.1089/adt.2006.053. PubMed: 17355205.
24. Jacobs JP, Jones CM, Baille JP, (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227: 168-170. doi:10.1038/227168a0. PubMed: 4316953.
25. Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr, (1963) The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23: 1390-1427. PubMed: 14070392.
26. Mazerski J, Martelli S, Borowski E, (1998) The geometry of intercalation complex of antitumor mitoxantrone and ametantrone with DNA: molecular dynamics simulations. Acta Biochim Pol 45: 1-11. PubMed: 9701490.
27. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, et al. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343: 1750-1757. doi:10.1056/NEJM200012143432402. PubMed: 11114313.
28. Takimoto CH, Calvo E, (2008) Principles of Oncologic Pharmacotherapy. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach, 11 ed.
29. Kean WF, Hart L, Buchanan WW, (1997) Auranofin. Br J Rheumatol 36: 560-572. doi:10.1093/rheumatology/36.5.560. PubMed: 9189058.
30. Gandin V, Fernandes AP, Rigobello MP, Dani B, Sorrentino F, et al. (1981) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem Pharmacol 41: 94-97. PubMed: 19665452.
31. Simon TM, Kunishima DH, Vibert GJ, Lorber A, (1985) Screening trial with the coordinated gold compound auranofin using mouse lymphocytic leukemia P388. Cancer Res 45: 32-39. PubMed: 3917372.
32. Rao R, Maddocks K, Johnson AJ, Chauhan L, Kambhampati S, et al. (2011) Treatment with auranofin induces oxidative and lethal endoplasmic reticulum (ER) stress exerting single agent activity against primary CLL cells. Blood (ASH Annual Meeting Abstracts) 118: 929.
33. Saba N, Shen M, Ghias M, Farooqui M, Austin CP, et al. (2012) The gold compound auranofin induces oxidative stress and apoptosis in primary CLL cells independent of classic prognostic markers and the protective effect of the tissue microenvironment. Blood (ASH Annual Meeting Abstracts) 120: 865.
34. Clinical trials website. Available: http://www.clinicaltrials.gov/ct2/show/NCT01419691?term=auranofin+CLL&rank=1. Accessed 2013 August 18.
35. Egger G, Liang G, Aparicio A, Jones PA, (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
36. Derissen EJ, Beijnen JH, Schellens JH, (2013) Concise drug review: azacitidine and decitabine. Oncologist 18: 619-624. doi:10.1634/theoncologist.2012-0465. PubMed: 23671007.
37. Issa JP, Kantarjian HM, Kirkpatrick P, (2005) Azacitidine. Nat Rev Drug Discov 4: 275-276. doi:10.1038/nrd1698. PubMed: 15861567.
38. Von Hoff DD, Slavik M, Muggia FM, (1976) 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85: 237-245. doi:10.7326/0003-4819-85-2-237. PubMed: 60073.
39. Clinical trials website. Available: http://www.clinicaltrials.gov/ct2/show/NCT00413478?term=CLL+azacitidine+celgene&rank=2. Accessed 2013 August 18.
40. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, et al. (2012) Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: A phase II study. Clin Lymphoma Myeloma Leuk 13: 292-295. PubMed: 23265768.
41. Vilensky JA, Redman K, (2003) British anti-Lewisite (dimercaprol): an amazing history. Ann Emerg Med 41: 378-383. doi:10.1067/mem.2003.72. PubMed: 12605205.
42. Drug information website. Available: http://www.drugs.com/mtm/dimercaprol.html. Accessed 2013 August 18.
43. Denny-Drown D, Porter H, (1951) The effect of bal (2,3-dimercaptopropanol) on hepatolenticular degeneration (wilson's disease). N Engl J Med 245: 917-925.
44. Mückter H, Liebl B, Reichl FX, Hunder G, Walther U, et al. (1997) Are we ready to replace dimercaprol (BAL) as an arsenic antidote? Hum Exp Toxicol 16: 460-465. doi:10.1177/096032719701600807. PubMed: 9292286.
45. Xu H, Lv M, Tian X, (2009) A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr Med Chem 16: 327-349. doi:10.2174/092986709787002682. PubMed: 19149581.
46. You Y, (2005) Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des 11: 1695-1717. doi:10.2174/1381612053764724. PubMed: 15892669.
47. Canel C, Moraes RM, Dayan FE, Ferreira D, (2000) Podophyllotoxin. Phytochemistry 54: 115-120. doi:10.1016/S0031-9422(00)00094-7. PubMed: 10872202.
48. Yarbro JW, Kennedy BJ, Barnum CP, (1968) Mithramycin inhibition of ribonucleic acid synthesis. Cancer Res 26: 36-39. PubMed: 5901746.
49. Kennedy BJ, Torkelson JL, (1995) Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin). Med Pediatr Oncol 24: 327-328. doi:10.1002/mpo.2950240511. PubMed: 7700186.
50. Archimbaud E, Troncy J, Sebban C, Guyotat D, Devaux Y, et al. (1989) Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia. Cancer Chemother Pharmacol 25: 223-225. doi:10.1007/BF00689589. PubMed: 2532073.
51. Dutcher JP, Coletti D, Paietta E, Wiernik PH, (1997) A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. Leuk Res 21: 375-380. doi:10.1016/S0145-2126(96)00108-7. PubMed: 9225062.
52. Tournilhac O, Cazin B, Leprètre S, Diviné M, Maloum K, et al. (2004) Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 103: 363-365. doi:10.1182/blood-2003-05-1449. PubMed: 12969985.
53. Bosch F, Ferrer A, Villamor N, González M, Briones J, et al. (2008) Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 14: 155-161. doi:10.1158/1078-0432.CCR-07-1371. PubMed: 18172266.